NCT00816361View on ClinicalTrials.gov

A Dose-escalation Study to Evaluate the Safety, Tolerability, and Antitumor Activity of MEDI-573 in Subjects With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

March 9, 2009

Primary Completion Date

September 11, 2012

Study Completion Date

September 11, 2012

Conditions
Cancer
Interventions
DRUG

MEDI-573

Administered at a dose determined by the subject's enrollment cohort as an IV infusion as part of a 21 day treatment cycle.

Trial Locations (6)

19111

Research Site, Philadelphia

32224

Research Site, Jacksonville

48201

Research Site, Detroit

55905

Research Site, Rochester

85259

Research Site, Scottsdale

02115

Research Site, Boston

Sponsors

Lead Sponsor

MedImmune LLC
All Listed Sponsors
lead

MedImmune LLC

INDUSTRY